Abstract: According to the present invention, a crystal of reduced glutathione having a reduced content of impurities, particularly L-cysteinyl-L-glycine and a method for producing the same are provided. The present invention relates to a crystal of reduced glutathione, wherein, in a high-performance liquid chromatography (HPLC) analysis, the peak area of L-cysteinyl-L-glycine is 0.02 or less with respect to the peak area of reduced glutathione which is taken as 100.

Abstract: An aminoalkylthiosulfuric acid compound represented by formula (1): is produced. In step (A1), a hydrochloride of a chloroalkylamine compound represented by formula (2): is reacted with an alkali metal salt of thiosulfuric acid in the presence of 2 to 6 parts by weight of water with respect to 1 part by weight of the hydrochloride between 50° C. and 100° C. R1 and R2 each represents a hydrogen atom and the like, and n represents an integer of 2 to 9. In step (B1), a mixture of a solid containing the aminoalkylthiosulfuric acid compound and a liquid containing an alkali metal chloride is obtained by adjusting the temperature of the mixture of step (A1) to between ?15° C. and 50° C. In step (C1), the aminoalkylthiosulfuric acid compound is obtained as solid by separating the solid containing the aminoalkylthiosulfuric acid compound and the liquid containing the alkali metal chloride from the mixture of (B1).

Abstract: Disclosed is a crystal of glutathione having an average width of 7 to 40 ?m and an average particle diameter of 10 to 60 ?m, preferably having an angle of repose of 53 degree or less, more preferably having a crude specific volume of 5.0 cm3/g or less, still more preferably in the form of an alpha-form crystal. Also disclosed is a tablet containing such a crystal of glutathione. Further disclosed is a process for producing such a crystal of glutathione.

Abstract: The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of such a protein and a pharmaceutical composition containing it are highly useful for proliferative diseases, particularly as anticancer agents. By providing the novel target protein, the mechanism behind the anticancer effect that has conventionally been unexplainable can be elucidated.

Abstract: One aspect of the present invention relates to ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in various transition-metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition-metal-catalyzed reactions, including the range of suitable substrates, number of catalyst turnovers, reaction conditions, and efficiency. For example, improvements have been realized in transition metal-catalyzed: aryl amination reactions; aryl amidation reactions; Suzuki couplings; and Sonogashira couplings. In certain embodiments, the invention relates to catalysts and methods of using them that operate in aqueous solvent systems.

Abstract: One aspect of the present invention relates to ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in various transition-metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition-metal-catalyzed reactions, including the range of suitable substrates, number of catalyst turnovers, reaction conditions, and efficiency. For example, improvements have been realized in transition metal-catalyzed: aryl amination reactions; aryl amidation reactions; Suzuki couplings; and Sonogashira couplings. In certain embodiments, the invention relates to catalysts and methods of using them that operate in aqueous solvent systems.

Abstract: The present invention relates to a process for producing amino/guanidinothiosulfonic acid, which comprises treating a styrenedivinylbenzene copolymer sulfonate of amino/guanidinoethyl disulfoxide into contact with an alkali, selectively eluting amino/guanidinosulfinic acid, then reacting this product in a non-aqueous solvent in the presence of a base, and passing the reaction product through a weakly acidic cation exchange resin column; in accordance with the present invention, hypotaurine, thiotaurine and the like having a high purity can industrially be produced.

Abstract: Taurine analogues are used for scavenging active oxygen compounds and preventing and minimizing damage to the skin from ultraviolet rays. The taurine analogues have the following formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification.

Abstract: Novel aryl ethers, containing both a carboxylic acid and a sulfonic acid functionality; and a process for making them are described. These difunctional aryl compounds comprise:i) a carboxylic acid group or its derivative,ii) a first aromatic group bonded to the carboxylic acid or its derivative,iii) a second aromatic group linked to the first aromatic group by a non-electron-withdrawing moiety,iv) a third aromatic group linked to the second aromatic group by a non-electron-withdrawing moiety, andv) a sulfonyl group or its derivative bonded to the third aromatic group.

Abstract: The invention relates to a process for the preparation of compounds of the formula ##STR1## in which Q is substituted or unsubstituted C.sub.1 -C.sub.6 alkyl, A is a direct bond or a bridging member, s is the number 1 or 2, Z is a radical of the formula --CH.sub.2 CH.sub.2 OH, --CH.dbd.CH.sub.2 or --CH.sub.2 CH.sub.2 --Y, and Y is a leaving group, and the benzene or napthalene nucleus I can be further substituted, which comprises reacting compounds of the formula ##STR2## with compounds of the formulaQ--OH (3)in which A, s, Z and Q are as defined under formula (1), in the presence of hydrogenation catalysts, and then carrying out further conversion reactions where appropriate.The compounds obtained by the process according to the invention are suitable as intermediates for the preparation of reactive dyes.

Abstract: A compound of the formula ##STR1## in which R.sub.1 and R.sub.2 independently of one another are each C.sub.1 -C.sub.10 alkyl which is unsubstituted or substituted by hydroxyl, C.sub.1 -C.sub.4 alkoxy, phenyl, sulfo, sulfato, thiosulfato, cyano or halogen, C.sub.5 -C.sub.7 cycloalkyl which is unsubstituted or substituted by halogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkoxy, or phenyl or naphthyl which both are unsubstituted or substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkanoylamino, benzoylamino, halogen or sulfo, R.sub.3 is hydrogen, halogen, C.sub.1 -C.sub.10 alkyl which is unsubstituted or substituted by hydroxyl, C.sub.1 -C.sub.4 alkoxy, phenyl, sulfo, sulfato, thiosulfato, cyano or halogen, C.sub.1 -C.sub.10 alkoxy which is unsubstituted or substituted by C.sub.1 -C.sub.4 alkoxy, or phenoxy which is unsubstituted or substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.